...BRCA2). Median TTP was 2.14 months and median OS was 7.8 months. Intracranial RR was 12 %, while intracranial CBR was 27...
...BRCA2 gene). NGS offers promise, but poses significant challenges for oncologists who are ill prepared to handle inciden...
...BRCA2 mutation; 150 (74.6 %) patients underwent NSM for risk reduction and 51 (25.4 %) for cancer. Incidental cancers we...
...BRCA2. Breast cancer incidence for BRCA2 was marginally higher than BRCA1 at 20.05 per 1000 in BRCA2 compared with 16.20...
...BRCA2. Here, we investigate why, paradoxically, mutations in HR genes protect cells from killing by gemcitabine. Using D...
...BRCA2 germ line mutation. They will be identified via our Genetic counseling unit. All men after signing an informed con...
...BRCA2 mutations (cumulative incidence of 45%). Gynecological and gonadal tumors are frequent as well and can be more (ad...
...BRCA2 genes. Some recent studies demonstrated that BRCA1 mutations are seen in high-risk women with family histories of ...
BRCA1 and BRCA2 are the most well-known breast and ovarian cancer susceptibility genes. Additional genes involved in DNA...
...BRCA2 mutation carriers (BRCA2 carriers) older than 60 in the Northern Netherlands, and to analyze whether these could b...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
